Clinical trials: Virus Diseases
Influenza
Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza
This protocol will seek to enroll 372 adult otherwise healthy subjects presenting with influenza-like illness (ILI). Subjects will enter the study based on listed inclusion/exclusion criteria, including a positive Rapid Antigen…
- Trial name
- NCT01740063
- Testing
- DAS181-F02 formulation, DAS181-F04 formulation
- Where
- United States
- Volunteers
- 423 people
- Sponsor
- Ansun Biopharma, Inc.
HIV Infections
Study of Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz.
To compare tenofovir DF plus lamivudine plus efavirenz vs. stavudine plus lamivudine plus efavirenz in the treatment of HIV-1-infected patients who have never taken antiretroviral drugs and have a viral load of less than 400…
- Trial name
- NCT00158821
- Testing
- Viread (tenofovir disoproxil fumarate), Sustiva (Efavirenz), Epivir (Lamivudine)
- Volunteers
- 180 people
- Sponsor
- Gilead Sciences
HIV Infections
A Comparison of Two Dose Levels of Indinavir Combined With Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients
The purpose of this study is to determine if two dose levels of indinavir combined with two nucleoside analogue reverse transcriptase inhibitors (NRTIs) have the same effect on plasma viral load (level of HIV in the blood).
- Trial name
- NCT00002406
- Testing
- Indinavir sulfate
- Where
- 29 sites in United States
- Volunteers
- 350 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
Assessing Choice in the Employer Setting (ACES) Study
The purpose of this study is to determine, among adults and in the total population, the effects of offering a choice of FluMist or trivalent inactivated vaccine (TIV) in the employer setting when compared to a control group.
- Trial name
- MA181 (NCT00808808)
- Testing
- Choice of TIV or FluMist with baseline advertisement, Choice of TIV or FluMist with enhanced advertisement and incentives, Control - Usual care offering TIV only with baseline advertisement
- Where
- 47 sites in United States
- Volunteers
- 4,411 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
COVID-19, Vaccine Reaction
The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001
The goal of this clinical trial is to assess the immunogenicity and safety following a heterologous booster dose of recombinant SARS-CoV-2 vaccine (CHO cell) LYB001 in adults 18-59 years of age completed two- or three-dose…
- Trial name
- NCT05928455
- Testing
- LYB001, CoronaVac
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
COVID-19
A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions.
The purpose of this study is to learn about the effects of the study medicine called Paxlovid [nirmatrelvir-ritonavir/PF-07321332], for the potential treatment of COVID-19.
- Trial name
- NCT07261085
- Testing
- nirmatrelvir-ritonavir, No treatment
- Where
- United States
- Volunteers
- 99,000 people
- Sponsor
- Pfizer
COVID-19
A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults
The purpose of this trial is to evaluate immunogenicity and safety of CVXGA administered as a single intranasal dose against SARS-CoV-2 S-protein in participants.
- Trial name
- NCT05736835
- Testing
- CVXGA
- Where
- 10 sites in United States
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- CyanVac LLC
COVID, SARS-CoV2
Evaluation of an Alternative Method of Obtaining Viral RNA for the Detection of SARS-CoV-2 Virus Using PCR
The current coronavirus disease pandemic has posed a problem and a challenge for health systems globally. In the framework of a pandemic, a diagnosis is a key tool in containing and monitoring disease outbreaks.
- Conditions
- COVID, SARS-CoV2, Corona Virus Infection
- Trial name
- NCT04468217
- Testing
- Obtainment of nasopharyngeal, oropharyngeal, buccal, nasal and saliva samples
- Where
- Chile
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Neurognos
COVID-19, Corona Virus Infection
A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19
Agent Name and Study Duration ArtemiC is a medical spray comprised of Artemisinin (6 mg/ml), Curcumin (20 mg/ml), Frankincense (=Boswellia) (15 mg/ml) and vitamin C (60 mg/ml) in micellar formulation for spray administration.
- Conditions
- COVID-19, Corona Virus Infection, SARS-CoV 2, Coronavirus
- Trial name
- NCT04382040
- Testing
- ArtemiC
- Where
- 4 sites in India, Israel
- Volunteers
- 50 people
- Sponsor
- MGC Pharmaceuticals d.o.o
SARS-CoV Infection, Covid19
International Registry of Healthcare Workers Exposed to COVID-19 Patients (UNITY Global)
The International Registry of Healthcare Workers Exposed to COVID-19 Patients (UNITY Global), is an international registry of approximately 10,000 healthcare workers in low- and middle-income countries experiencing increasing…
- Trial name
- NCT04626076
- Testing
- Comparative Observational Cohort Study
- Where
- Pakistan
- Volunteers
- 6,808 people, healthy volunteers welcome
- Sponsor
- Certara
Common Cold
Evaluation of ColdZyme® on Experimentally Induced Common Cold.
This study evaluates the performance of ColdZyme® mouth spray on prevention of common cold symptoms on experimentally induced rhinovirus upper respiratory tract infection in healthy volunteers.
- Trial name
- COLDPREVII (NCT02479750)
- Testing
- ColdZyme® mouth spray
- Where
- United Kingdom
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Enzymatica AB
Hepatitis B, Diphtheria
Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separately
This study will assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' (formerly SB Biologicals') DTPa-HBV-IPV/Hib (Infanrix hexa™) vaccine compared with separate administration of DTPa-HBV-IPV (Infanrix…
- Conditions
- Hepatitis B, Diphtheria, Haemophilus Influenzae Type b (Hib), Poliomyelitis
- Trial name
- NCT01457508
- Testing
- DTPa-HBV-IPV/Hib (Infanrix hexa™), DTPa-HBV-IPV (Infanrix penta™), Hib (Hiberix™)
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study
This is a dose exploration study to evaluate the safety and pharmacokinetics (PK) of AZD3152 in healthy adult male and female participants, across different dose levels and routes of administration (ie, Intramuscular [IM]…
- Trial name
- NCT05872958
- Testing
- AZD3152
- Where
- 4 sites in United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Malignant Melanoma
A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma
The purpose of this study is to determine if HF10 in combination with ipilimumab is effective in patients with stages IIIB, IIIC, or IV unresectable or metastatic melanoma.
- Trial name
- NCT02272855
- Testing
- HF10 plus Ipilimumab
- Where
- 8 sites in United States
- Volunteers
- 46 people
- Sponsor
- Takara Bio Inc.
AIDS
Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc
The objective of this study was to estimate the effects of a single dose of vardenafil on the blood pressure (BP) in subjects receiving maraviroc (MVC) (dosed to steady-state) and to assess the safety and tolerability of MVC in…
- Trial name
- NCT00853840
- Testing
- Maraviroc, Vardenafil
- Where
- Belgium
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
COVID-19, Lymphocytopenia
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort
Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/ kg twice a week for two weeks on immune reconstitution of lymphopenic COVID-19 patients.
- Trial name
- ILIAD-7-FR (NCT04407689)
- Testing
- Interleukin-7
- Where
- 6 sites in France
- Volunteers
- 34 people
- Sponsor
- Revimmune
Respiratory Syncytial Virus Vaccination
First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults
First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults
- Trial name
- NCT06194318
- Testing
- Candidate vaccine, SCB-1019, candidate vaccine, SCB-1019T, AREXVY
- Where
- 2 sites in Australia
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
Influenza
Safety Study of an Adjuvanted Candidate Influenza Vaccine to Prevent Influenza Disease in the Elderly Population
As influenza vaccine efficacy is reported to be lower in elderly subjects compared to healthy adults, probably as a result of immunosenescence, there is a desire to devise ways to increase the current vaccines efficacy for this…
- Trial name
- NCT00318058
- Testing
- influenza vaccine Fluarix, Adjuvanted Fluarix
- Where
- Belgium
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Varicella-zoster Virus
Phase II Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above
The primary objective of this study is to evaluate the immunogenicity and safety of 2 injections (approximately 2 months apart) of ABO1108 in adults aged 40 years or above.
- Trial name
- NCT07285278
- Testing
- ABO1108
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
Chronic Hepatitis C
4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C
The purpose of this study is to determine if taking nitazoxanide alone for 4 weeks followed by 36 weeks of nitazoxanide plus peginterferon is superior to peginterferon plus ribavirin (standard of care) for 48 weeks.
- Trial name
- NCT00763568
- Testing
- Nitazoxanide, Peginterferon alfa-2a
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Romark Laboratories L.C.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.